Welcome to our dedicated page for Dare Bioscience SEC filings (Ticker: DARE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Daré Bioscience, Inc. filings document a women’s health biotechnology issuer with product and pipeline disclosures, operating-result updates, and capital-structure activity. Recent 8-K reports cover financial results, Regulation FD presentations, and unregistered sales tied to a Regulation A unit offering composed of Series A Convertible Preferred Stock and warrants to purchase common stock.
Proxy and governance filings describe annual meeting matters, director elections, executive compensation, equity awards, board classification, and stockholder voting procedures. The record also includes disclosure around offering statements, preferred-stock conversion terms, warrant exercise terms, and financing activity associated with advancing women’s health products and clinical programs.
Dare Bioscience director William H. Rastetter received a grant of stock options for 10,000 shares of common stock. The options have an exercise price of $2.03 per share and expire on June 11, 2036. They vest in full on the earlier of the first anniversary of the grant date or immediately before the company’s first annual shareholder meeting after the grant date, subject to his continued board service. The options also become fully exercisable upon a change in control of Dare Bioscience.
Dare Bioscience director Susan L. Kelley received a grant of stock options covering 10,000 shares of common stock. The options have an exercise price of $2.03 per share and expire on June 11, 2036. Following this award, she holds 10,000 stock options directly from this grant.
The option will vest in full on the earlier of the first anniversary of the grant date or immediately before the company’s first annual stockholders’ meeting after the grant, as long as she continues serving as a director. It will also become fully exercisable upon a change in control of Dare Bioscience.
Dare Bioscience, Inc. director Robin Joan Steele received a grant of stock options covering 10,000 shares of common stock. The options have an exercise price of $2.03 per share and expire on June 11, 2036.
The option will vest in full on the earlier of the first anniversary of the June 11, 2026 grant date or immediately prior to the company’s first annual meeting of stockholders occurring after that date, subject to Steele’s continued service as a director. The option also becomes fully exercisable upon a change in control of the company. Following this grant, Steele holds 10,000 stock options directly.
Dare Bioscience, Inc. director Gregory W. Matz received a grant of stock options covering 10,000 shares of common stock. The options have an exercise price of $2.03 per share and expire on June 11, 2036. They vest in full on the earlier of the first anniversary of the grant date or immediately before the first annual stockholder meeting after the grant date, subject to his continued board service, and become fully exercisable upon a change in control.
Dare Bioscience, Inc. director Jessica D. Grossman received a grant of stock options covering 10,000 shares of common stock. The options have an exercise price of $2.03 per share and expire on June 11, 2036.
According to the terms, the option will vest in full on the earlier of the first anniversary of the grant date or immediately before the company’s first annual stockholder meeting after the grant date, as long as she continues serving as a director. The options also become fully exercisable upon a change in control of the company. Following this grant, she holds 10,000 stock options directly.
Daré Bioscience, Inc. completed closings of its previously announced Regulation A unit offering. The company issued 50,000 Investor Units, each priced at $5.00, with each unit consisting of one share of Series A Convertible Preferred Stock and two Investor Warrants.
In total, Daré issued 50,000 shares of Series A Preferred Stock and Investor Warrants to purchase up to 100,000 shares of common stock. The offering is conducted under an offering statement on Form 1-A qualified by the SEC on April 1, 2026, with related offering circulars dated January 6, March 26, and May 14, 2026.
Daré Bioscience reported a Q1 2026 net loss of $3.0 million, improving from a $4.4 million loss a year earlier, on modest revenue of $152,455 from research and development services and royalties. Operating expenses fell significantly as research and development spending declined.
The company ended the quarter with $18.5 million in cash and cash equivalents and working capital of about $0.5 million, but most cash is tied to restricted grant funding. Management states there is substantial doubt about its ability to continue as a going concern over the next 12 months without additional capital.
Daré is pursuing a dual-path strategy in women’s health, combining traditional FDA product development with Section 503B compounding and consumer health offerings. To support operations, it is raising funds through a Regulation A preferred/warrant offering and an equity line with Lincoln Park, while also using royalty financing backed by XACIATO sales.
Daré Bioscience reported first quarter 2026 results, posting revenue of $152,455 and a net loss of $2,999,889, or $0.20 per share, compared to a $4,378,307 loss a year earlier. Revenue came mainly from research and development services and royalty income tied to Gates Foundation agreements.
Cash and cash equivalents were $18,519,784 and working capital was $540,124 as of March 31, 2026, both down from year-end 2025. Operating expenses decreased, with research and development spending falling sharply, aided by $3,500,000 of grant-related contra-R&D expense.
The company highlighted multiple upcoming catalysts, including anticipated first direct product revenue from Flora Sync LF5 in June 2026 and DARE to PLAY in the third quarter of 2026, as well as a second positive interim Data Safety Monitoring Board review from the Phase 3 Ovaprene contraceptive trial.
Daré Bioscience, Inc. completed multiple closings of its ongoing Regulation A unit offering. The company issued 195,010 Investor Units, each priced at $5.00 and consisting of one share of Series A Convertible Preferred Stock and two Investor Warrants to purchase common stock.
The completed closings on May 1, 4, 5 and 6, 2026 resulted in 195,010 shares of Series A Preferred Stock and Investor Warrants to purchase up to 390,020 shares of common stock. The offering is being conducted under an offering statement on Form 1-A qualified by the SEC on April 1, 2026.
Daré Bioscience, Inc. files its Form 10-K reporting a strategic shift to a dual-path commercial model that pursues FDA approvals and earlier market access via Section 503B compounding, plus consumer health product launches. The company began commercialization of DARE to PLAY sildenafil cream in December 2025 and expects sales and pharmacy dispensing to begin in Q2 2026. Pipeline priorities include a pivotal Phase 3 study of Ovaprene (monthly, hormone-free contraceptive), planned Phase 3 activity for Sildenafil Cream for FSAD, DARE-HRT1 intravaginal ring for menopause symptoms, and ARPA-H-funded development of DARE-HPV. The company disclosed 14,559,502 shares outstanding as of March 25, 2026 and an aggregate market value of non-affiliate shares of approximately $21,339,826 as of its most recent second fiscal quarter.